Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 23, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 23, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 2,388 Common Stock at $488.70 ($1,167,007) on September 23, 2026; holds 331,555 after (Indirect).
- Open-market sale: disposed of 2,162 Common Stock at $489.52 ($1,058,351) on September 23, 2026; holds 329,393 after (Indirect).
- Open-market sale: disposed of 1,440 Common Stock at $490.48 ($706,286) on September 23, 2026; holds 327,953 after (Indirect).
- Open-market sale: disposed of 824 Common Stock at $491.65 ($405,124) on September 23, 2026; holds 327,129 after (Indirect).
- Open-market sale: disposed of 480 Common Stock at $492.54 ($236,421) on September 23, 2026; holds 326,649 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $493.72 ($78,996) on September 23, 2026; holds 326,489 after (Indirect).
- Open-market sale: disposed of 155 Common Stock at $495.17 ($76,752) on September 23, 2026; holds 326,334 after (Indirect).
- Open-market sale: disposed of 525 Common Stock at $496.38 ($260,598) on September 23, 2026; holds 325,809 after (Indirect).
- Open-market sale: disposed of 766 Common Stock at $497.27 ($380,908) on September 23, 2026; holds 325,043 after (Indirect).
- Open-market sale: disposed of 270 Common Stock at $498.38 ($134,563) on September 23, 2026; holds 324,773 after (Indirect).
- Open-market sale: disposed of 90 Common Stock at $498.90 ($44,901) on September 23, 2026; holds 324,683 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $500.05 ($120,012) on September 23, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 23, 2026; holds 375,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,669,918 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-23 | Open-market sale | Common Stock | 2,388 | $489 | $1.2M | 331,555 |
| 2026-09-23 | Open-market sale | Common Stock | 2,162 | $490 | $1.1M | 329,393 |
| 2026-09-23 | Open-market sale | Common Stock | 1,440 | $490 | $706.3K | 327,953 |
| 2026-09-23 | Open-market sale | Common Stock | 824 | $492 | $405.1K | 327,129 |
| 2026-09-23 | Open-market sale | Common Stock | 480 | $493 | $236.4K | 326,649 |
| 2026-09-23 | Open-market sale | Common Stock | 160 | $494 | $79.0K | 326,489 |
| 2026-09-23 | Open-market sale | Common Stock | 155 | $495 | $76.8K | 326,334 |
| 2026-09-23 | Open-market sale | Common Stock | 525 | $496 | $260.6K | 325,809 |
| 2026-09-23 | Open-market sale | Common Stock | 766 | $497 | $380.9K | 325,043 |
| 2026-09-23 | Open-market sale | Common Stock | 270 | $498 | $134.6K | 324,773 |
| 2026-09-23 | Open-market sale | Common Stock | 90 | $499 | $44.9K | 324,683 |
| 2026-09-23 | Open-market sale | Common Stock | 240 | $500 | $120.0K | 324,443 |
| 2026-09-23 | Option exercise/conversion | Stock Option | 9,500 | — | — | 375,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Option exercise/conversion (9,500 shares) |
| 2026-09-23 | Open-market sale (2,388 shares) |
| 2026-09-23 | Open-market sale (2,162 shares) |
| 2026-09-23 | Open-market sale (1,440 shares) |
| 2026-09-23 | Open-market sale (824 shares) |
| 2026-09-23 | Open-market sale (480 shares) |
| 2026-09-23 | Open-market sale (160 shares) |
| 2026-09-23 | Open-market sale (155 shares) |
| 2026-09-23 | Open-market sale (525 shares) |
| 2026-09-23 | Open-market sale (766 shares) |
| 2026-09-23 | Open-market sale (270 shares) |
| 2026-09-23 | Open-market sale (90 shares) |
| 2026-09-23 | Open-market sale (240 shares) |
| 2026-09-23 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.